 "South Africa's Adcock Ingram sells Indian business to Samara Capital for Rs 151 crores")
The South African pharmaceutical company Adcock Ingram Holdings Limited has entered into a definitive agreement to sell its Indian operation, Adcock Ingram Healthcare Private Limited (Adcock Healthcare), to Samara Capital Partners Fund II Limited - an India focused private equity firm - for Rs 151 crore.
Adcock Healthcare’s regulatory services business has been excluded from this deal, which was signed on April 6, 2016. The regulatory services business provides transactional back office support service in the areas of regulatory services (drug dossiers, regulatory filings, etc), quality control and assurance, medical affairs, information technology support and R&D services to Adcock.
“The Indian pharmaceutical business does not meet the company’s current investment criteria and as a result the company has decided to exit this business,” said Adcock Ingram in a press release explaining the rationale behind the divestment. The disposed business was acquired by Adcock Ingram in 2013 from Cosme Farma Laboratories for about Rs 328 crore to tap the Indian pharmaceutical segment.
Adcock Ingram expects to complete the disposal process by the end of July 2016.
Adcock Healthcare’s regulatory services business has been excluded from this deal, which was signed on April 6, 2016. The regulatory services business provides transactional back office support service in the areas of regulatory services (drug dossiers, regulatory filings, etc), quality control and assurance, medical affairs, information technology support and R&D services to Adcock.
“The Indian pharmaceutical business does not meet the company’s current investment criteria and as a result the company has decided to exit this business,” said Adcock Ingram in a press release explaining the rationale behind the divestment. The disposed business was acquired by Adcock Ingram in 2013 from Cosme Farma Laboratories for about Rs 328 crore to tap the Indian pharmaceutical segment.
Adcock Ingram expects to complete the disposal process by the end of July 2016.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%